Related Experiment Video
Updated: Jun 23, 2026
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Pathophysiological targets for beta-blocker therapy in congestive heart failure
1Medizinische Universitätsklinik Freiburg im Breisgau Abteilung Innere Medizin III/Kardiologie, Angiologie, Germany.
European Heart Journal
|April 1, 1996
Summary
Beta-blockers improve congestive heart failure by reducing heart rate, which optimizes contractile performance in failing hearts. This heart rate reduction is key to the therapeutic benefits of beta-blockade in chronic heart failure.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Congestive heart failure (CHF) treatment has evolved, with neurohumoral inhibition becoming a key principle.
- ACE-inhibitors and beta-blockers show significant benefits in CHF patients.
- The exact mechanisms of beta-blocker efficacy in CHF require further elucidation.
Purpose of the Study:
- To investigate the precise mechanisms underlying the therapeutic benefits of beta-blockade in congestive heart failure.
- To explore the role of heart rate reduction in beta-blocker efficacy.
- To understand the altered myocardial calcium handling in chronic heart failure.
Main Methods:
- Review of existing literature on CHF treatment and beta-blocker mechanisms.
- Analysis of myocardial phenotype changes in chronic heart failure, including enzyme activity and expression.
- Examination of calcium homeostasis alterations and their impact on contractile performance.
- Correlation of cytosolic calcium levels with contractile performance at varying heart rates.
Main Results:
- In chronic heart failure, the myocardium exhibits altered calcium handling, with decreased sarcoplasmic reticulum calcium ATPase (SERCA) activity and increased sarcolemmal sodium-calcium exchanger activity.
- This leads to reduced contractile performance, particularly an inverse force/frequency relationship where performance declines with increasing heart rates.
- Studies indicate optimal contractile performance at significantly lower heart rates (e.g., 30 bpm).
- Photoluminescence markers show a direct correlation between cytosolic calcium and contractile performance across different heart rates.
Conclusions:
- Heart rate reduction achieved by beta-blockade is a primary contributor to their therapeutic benefits in chronic congestive heart failure.
- Altered myocardial calcium handling and the resulting force/frequency relationship are critical factors in CHF pathophysiology.
- Targeting heart rate may be a crucial strategy for managing CHF.
Related Concept Videos
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...